WBRT + stereotactic boost (n = 84) N patients (%) | WBRT alone (n = 168) N patients (%) | |
---|---|---|
Fractionation of WBRT | ||
5 x 4 Gy (n = 33) | 11 (13) | 22 (13) |
Longer-course WBRT (n = 219) | 73 (87) | 146 (87) |
Age at WBRT | ||
≤58 years (n = 132) | 44 (52) | 88 (52) |
≥ 59 years (n = 120) | 40 (48) | 80 (48) |
Gender | ||
Female (n = 150) | 50 (60) | 100 (60) |
Male (n = 102) | 34 (40) | 68 (40) |
Karnofsky performance score | ||
70 (n = 78) | 26 (31) | 52 (31) |
≥80 (n = 174) | 58 (69) | 116 (69) |
Type of primary tumor | ||
Breast cancer (n = 69) | 23 (27) | 46 (27) |
Lung cancer (n = 156) | 52 (62) | 104 (62) |
Other cancers (n = 27) | 9 (11) | 18 (11) |
Number of cerebral metastases | ||
1 (n = 120) | 40 (48) | 80 (48) |
2-3 (n = 132) | 44 (52) | 88 (52) |
Extracerebral metastases | ||
No (n = 114) | 38 (45) | 76 (45) |
Yes (n = 138) | 46 (55) | 92 (55) |
RPA class | ||
Class 1 (n = 90) | 30 (36) | 60 (36) |
Class 2 (n = 162) | 54 (64) | 108 (64) |
Interval from cancer diagnosis to WBRT | ||
≤ 15 months (n = 120) | 40 (48) | 80 (48) |
≥ 16 months (n = 132) | 44 (52) | 88 (52) |